United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2016_register executive 2016-04-19 article Notices D09002ee1c7f64bca D09002ee1c7f64c38 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled "CB1 receptor mediating compounds": 81 FR 22995 https://www.govinfo.gov/app/details/FR-2016-04-19/2016-08985 2016-08985 fr19ap16-47 4140-01-P https://www.govinfo.gov/app/details/FR-2016-04-19/2016-08985 https://www.govinfo.gov/content/pkg/FR-2016-04-19/html/2016-08985.htm https://www.govinfo.gov/content/pkg/FR-2016-04-19/pdf/2016-08985.pdf 1 p. 22995 22995 81 FR 22995 Prospective Grant of Exclusive License: Development of the CB1/iNOS Series of Compounds as a Therapeutic To Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans; Federal Register Vol. 81, Issue NOTICE 2016-08985 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2016-05-04 4140-01-P 2016-08985 Notice.

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled "CB1 receptor mediating compounds":

Only written comments and/or applications for a license which are received by the Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases on or before May 4, 2016 will be considered. Exclusive Licenses: Development of the CB1/iNOS Series of Compounds as a Therapeutic to Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans , betty.tong@nih.gov Vol. 81, no. 75 Office of the Federal Register, National Archives and Records Administration 2016-04-19 continuing daily deposited born digital 253 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2016-04-19 P0b002ee18f3aea1b 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr19ap16 https://www.govinfo.gov/app/details/FR-2016-04-19 https://www.govinfo.gov/content/pkg/FR-2016-04-19/pdf/FR-2016-04-19.pdf https://www.govinfo.gov/content/pkg/FR-2016-04-19/xml/FR-2016-04-19.xml fdlp 22911 23154 DGPO 2016-04-19 2024-06-02 FR-2016-04-19 machine generated eng FR FR-2016-04-19 81 75